Howard Lake | 30 June 2008 | News 23 total views, 1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. Tagged with: Major gift Volunteering Winning Words: A Volunteer’s Guide to Asking for Major Gifts
Local NewsBusiness By Digital AIM Web Support – February 22, 2021 Facebook Twitter Facebook TAGS WhatsApp Applebee’s Satisfies Cravings with NEW Boneless Wings and Handcrafted Burger Deal Pinterest Pinterest Twitter WhatsApp Applebee’s Satisfies Cravings with NEW Boneless Wings and Handcrafted Burger Deal Previous articleCarvana Unveils NTT INDYCAR SERIES Paint Scheme for No. 48 HondaNext articleLabelmaster Launches Online 3D Hazmat Training Experiences Digital AIM Web Support
Support for the CMIF began after FAMAE reported $2.6 million in profits during fiscal year 2014, recording sales of $56.1 million that year — an increase of 7.38 percent compared to 2013. Its supply division, which acquires replacement parts, raw materials and direct purchases, contributed 50 percent of FAMAE’s total revenue; its services section, which maintains armored vehicles, contributed 33 percent of its revenue. Product portfolio Sincerely,Tony Lyons.Eng. Mgr.Cell: 713 349 3773www.robcoamerica.com FAMAE’s also planning to manufacture ammunition under international standards, such as those of the North Atlantic Treaty Organization (NATO). Currently, it maintains commercial relations with the United States, Canada, Israel, Spain, Germany, Uruguay and Ecuador. The facility was built to improve maintenance for the entire ground fleet of the 3rd Armored Brigade “La Concepción” in the north while providing services to other countries; the project is part of FAMAE’s strategic plan, which also includes other investments intended to strengthen support for the Army and other branches of the country’s Armed Forces. It’s also working to open its “business portfolio, with both products and services, to other potential international markets at a competitive cost,” said FAMAE Director and Brigadier General Mauricio Heine. Building on positive results The Colombian service members were accompanied on a tour of the light armament and ammunition plants, and the industrial maintenance center, where they learned the company’s capabilities and its maintenance services and solutions. The service members also participated in shooting practice on the firing range. Brigadier General Heine attributed the company’s success to its employees’ focus on research and innovation. “We have been able to come up with solutions to problems of obsolete technology with recycling materials and more efficient designs of products and services,” he added. We would like to offer our services for your future sealing requirements. The Chilean Army Factory and Armory (FAMAE) opened its new Industrial Maintenance Center (CMIF), a 1,335 square-meter complex in the northern city of Antofagasta, on July 16. Among the designs FAMAE is developing for the international market is a new version of the SG 542-1 (5.56mm) rifle, which includes ergonomic and interface elements that allow the user to incorporate accessories and enable the soldier to use the weapon better. By Dialogo July 27, 2015 My name is Tony Lyons with Robco of America here in Houston, Texas.We are a Mechanical Seal manufacturing & repair service company.We offer fast turnarounds & competitive costs. “[Since this involves a domestically-manufactured product], we will be able to provide support during its entire life cycle,” Brigadier General Heine said. “We will be able to incorporate technological innovation processes, expanding our capabilities and applications according to market demand. Therefore, we will be able to keep the portfolio using a product family concept.” During its 204-year history, FAMAE – the oldest Military government-owned company in Latin America – has a record of developing technological innovations to meet market demands. Armed Forces officials from countries throughout the region often visit FAMAE facilities. “They come to learn about the business model being used by FAMAE for the Army and other defense institutions,” Brigadier General Heine said. “[The Colombian military delegation’s visit] gave us a positive impression because we are considered to be a reference point for the Latin American defense industry,” Brigadier General Heine said. In its sights In mid-May, delegates from the Colombian National Army toured FAMAE’s facilities, a visit that was permitted because it was within the framework of the 1st Bilateral Meeting of Army Chiefs of Staff for Colombia and Chile, which was held in the Chilean capital of Santiago.
– Advertisement – A heath worker injects the ‘Gam-COVID-Vac’, also known as ‘Sputnik V’, Covid-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), into a patients arm during a post-registration phase trial at the City Clinic #46 in Moscow, Russia, on Wednesday, Sept. 23, 2020.Bloomberg | Bloomberg | Getty Images Russia said Wednesday its coronavirus vaccine is 92% effective at preventing people from getting Covid-19, based on interim trial results.The announcement by Russia’s sovereign wealth fund RDIF came two days after U.S. pharmaceutical giant Pfizer and its German partner BioNTech said their vaccine was more than 90% effective in phase three trials.RDIF said the early results from its late-stage phase three clinical trial of the vaccine, called “Sputnik V,” showed that its efficacy was “based on the 20 confirmed Covid-19 cases split between vaccinated individuals and those who received the placebo.”- Advertisement – Observation of study participants will continue for six months before a full report of the phase three clinical trials is presented, RDIF said, but it noted that the interim research data will be published by the Gamaleya Center team, which developed the vaccine, “in one of the leading international peer-reviewed medical journals” without indicating when this might be.Vaccine raceThe Pfizer/BioNTech analysis evaluated 94 confirmed Covid-19 infections among its trial’s 43,538 participants. The partners said the case split between vaccinated individuals and those who received a placebo indicated a vaccine efficacy rate of above 90% at seven days after the second dose.The latest announcement from Russia comes a day after Russia’s President Vladimir Putin announced that the country was developing a third vaccine. He also said Moscow was ready to cooperate with all other countries on vaccines but warned against the “politicization” of the process.Russia has itself been accused of engaging in a vaccine race as drugmakers around the world try to develop an effective protection against the virus that has caused over 1.2 million deaths worldwide, according to Johns Hopkins University data. Russia has the fifth highest number of confirmed coronavirus infections, with around 1.8 million cases reported to date. “Currently 40,000 volunteers are taking part in double-blind, randomized, placebo-controlled Phase III of Sputnik V clinical trials, out of which over 20,000 have been vaccinated with the first dose of the vaccine and more than 16,000 with both the first and second doses of the vaccine,” a statement published on the dedicated Sputnik V website said Wednesday.In August, Russia became the first country to register and approve a coronavirus vaccine. The announcement prompted concerns from some members of the international scientific community about the speed of the approval — the vaccine had not yet started phase three trials at that point — and lack of available data supporting Russian claims for the vaccine’s efficacy and safety.Russia published some data from early stage clinical trials in September and has repeatedly insisted that its vaccine is safe and effective. On Wednesday, RDIF said that “were no unexpected adverse events during the trials. Monitoring of the participants is ongoing.”- Advertisement – – Advertisement –